Can I Take Quercetin with Rezdiffra (Resmetirom)? A Women's Guide to This Supplement Interaction

Import from '@womanrx/ui'

What Is Resmetirom (Rezdiffra) and Why Women Are Taking It

Resmetirom is the first drug the FDA approved specifically for metabolic dysfunction-associated steatohepatitis (MASH, historically called NASH), receiving its approval on March 14, 2024 for adults with non-cirrhotic MASH and moderate-to-advanced liver fibrosis (stages F2-F3). MASH is not a gender-neutral disease.

MASH Has a Female Face

Women develop MASH through different hormonal pathways than men do. Estrogen is hepatoprotective during the reproductive years, which is one reason MASH prevalence rises sharply in perimenopause and post-menopause. A 2023 meta-analysis in Hepatology found that post-menopausal women had significantly higher rates of advanced fibrosis compared with pre-menopausal women of the same BMI. Women with PCOS also carry disproportionate MASH burden: a 2022 systematic review found NAFLD prevalence as high as 55% in women with PCOS, compared with approximately 25% in age-matched controls without PCOS.

How Resmetirom Works

Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. It selectively activates THR-beta receptors in the liver, increasing fatty acid oxidation, lowering liver fat, and reducing liver cell injury without the cardiac or bone effects of systemic thyroid hormone. In the MAESTRO-NASH trial, resmetirom 100 mg/day achieved MASH resolution in 29.9% of participants versus 9.7% for placebo at 52 weeks. Roughly half the trial participants were women, making the female-specific data more reliable than in many liver trials, though sex-stratified outcomes were not the primary endpoint.

The drug is dosed at 80 mg or 100 mg orally once daily, with dose selection based on body weight (<100 kg: 80 mg; 100 kg or above: 100 mg). Prescribing information confirms resmetirom is primarily metabolized by CYP3A4, which is the center of the quercetin interaction concern.

What Quercetin Actually Does in the Body

Quercetin is a flavonoid found in onions, apples, capers, and green tea, and it is widely sold as a supplement in doses ranging from 250 mg to 1,000 mg per day. Women reach for it for a range of reasons: allergy and sinus symptom relief, anti-inflammatory support, and increasingly for metabolic and liver health, since early-phase research suggests quercetin may reduce liver fat and inflammation.

Quercetin and CYP3A4: The Pharmacokinetic Problem

CYP3A4 is the most abundant drug-metabolizing enzyme in the human gut and liver. Quercetin inhibits CYP3A4 both in the intestinal wall and in the liver. A 2012 pharmacokinetic study in the European Journal of Clinical Pharmacology demonstrated that quercetin supplementation increased the area under the curve (AUC) of several CYP3A4-substrate drugs by 30-60%. Because resmetirom is a CYP3A4 substrate, quercetin inhibiting that enzyme could reduce resmetirom clearance and raise its plasma concentration above the intended therapeutic range.

This is not a theoretical risk you can dismiss. In vitro data show quercetin has an IC50 for CYP3A4 in the low-micromolar range, and gut-lumen concentrations after a 500 mg quercetin dose exceed that threshold. The practical meaning: resmetirom blood levels may climb in a way that amplifies both its desired effect and its side effects (nausea, diarrhea, hepatotoxicity signals).

Does the Inhibition Matter at Supplement Doses?

Here is where honesty about evidence gaps matters. No clinical study has directly measured the resmetirom-quercetin pharmacokinetic interaction in women or men. Resmetirom received FDA approval in March 2024, and the supplement interaction literature has not caught up. The CYP3A4 inhibition data for quercetin come from studies using other substrate drugs such as felodipine, nifedipine, and certain statins; the degree of interaction is substrate-dependent. Extrapolating to resmetirom is biologically reasonable but not yet directly confirmed.

A practical framework for estimating interaction risk before a trial-level study exists:

| Factor | Quercetin + Resmetirom | |---|---| | Is the drug a CYP3A4 substrate? | Yes (primary pathway per FDA label) | | Is the supplement a clinically meaningful CYP3A4 inhibitor? | Yes, moderate, at doses ≥500 mg/day | | Is the drug narrow therapeutic index? | Not classified as narrow, but dose-dependent liver signals exist | | Is the interaction directional (one drug raises the other)? | Yes: quercetin raises resmetirom exposure | | Female-specific modifier? | Women have lower CYP3A4 activity at baseline than men, which amplifies the net effect |

The last row of that table deserves a fuller explanation.

Women Have Lower Baseline CYP3A4 Activity

This is a sex-specific physiological fact that nearly every supplement interaction article ignores. Women express lower hepatic CYP3A4 protein than men on average, a finding documented in a 2001 clinical study published in Clinical Pharmacology and Therapeutics and confirmed in subsequent PK modeling. That means women start with somewhat less CYP3A4 capacity to clear resmetirom. Add quercetin-mediated inhibition on top of an already-lower baseline, and the potential for disproportionately elevated resmetirom exposure is greater in women than in men. This is not a reason to panic; it is a reason to be more careful about monitoring.

CYP3A4 activity also fluctuates across the menstrual cycle. Progesterone, dominant in the luteal phase, modestly induces CYP3A4, while estrogen effects are mixed. Women in post-menopause or taking progestin-containing hormonal therapy may experience a different interaction magnitude than cycling women.

Pharmacodynamic Overlap: A Secondary Concern

Beyond the pharmacokinetic interaction, quercetin and resmetirom share overlapping metabolic effects that may compound each other or, in theory, produce additive benefit. Whether additive effect is good or requires dose reconsideration is unknown.

Shared Liver Effects

Both agents reduce hepatic steatosis through partially overlapping mechanisms. Quercetin activates AMPK and PPARalpha, promoting fatty acid oxidation. Resmetirom activates THR-beta in hepatocytes to achieve similar end results. A 2021 pre-clinical study in Nutrients showed quercetin reduced liver triglycerides and improved insulin sensitivity in a murine MASH model. Whether this synergizes with or merely duplicates resmetirom's effects in humans is not established.

Anti-Inflammatory Effects

Quercetin inhibits NF-kB and reduces TNF-alpha and IL-6 production. Resmetirom's THR-beta agonism also has downstream anti-inflammatory effects in the liver. The pharmacodynamic overlap is speculative in the absence of combination human data, but it is worth noting for clinicians adjusting monitoring intervals.

Life-Stage Considerations: Who Is Most Affected

Reproductive Years (Ages 18-40) with PCOS

Women with PCOS are among the most likely to be prescribed resmetirom for MASH and also among the most likely to self-supplement with quercetin, because quercetin has been studied for PCOS-related insulin resistance. A 2021 randomized trial in Phytotherapy Research found that 500 mg/day quercetin improved insulin sensitivity markers in women with PCOS over 12 weeks. If you have PCOS and are on resmetirom, the temptation to add quercetin is understandable. The interaction risk, however, is a real pharmacokinetic concern at that 500 mg dose.

Perimenopause (Ages 40-55)

Liver fat accumulates faster in perimenopause because falling estrogen reduces hepatic fatty acid oxidation. Women in this stage may be more recently diagnosed with MASH and more likely to reach for supplements marketed for metabolic support. CYP3A4 activity in perimenopause is less well-characterized than in younger women, which adds another layer of uncertainty to predicting the interaction magnitude.

Post-Menopause

Post-menopausal women have higher MASH severity on average and are more likely to be on multiple medications. Polypharmacy increases the importance of mapping every CYP3A4 interaction carefully. Quercetin added to resmetirom in this context could interact not only with resmetirom but also with statin drugs (commonly CYP3A4 substrates) that many post-menopausal women take for cardiovascular risk.

Pregnancy, Lactation, and Contraception: Required Reading

Resmetirom is contraindicated in pregnancy. This is not a nuanced precaution. The FDA prescribing information carries a pregnancy contraindication based on embryofetal toxicity findings in animal studies. Per the Rezdiffra label, advise females of reproductive potential to use effective contraception during treatment and for one week after the final dose.

There are no adequate human data on resmetirom use in pregnant women. Human pregnancy exposure data have not been collected in any systematic registry as of the date of this article's review, given the drug's recent approval.

Lactation: It is not known whether resmetirom or its metabolites transfer into human breast milk. Because of the potential for serious adverse effects in a nursing infant, women should not breastfeed while taking resmetirom.

Quercetin in pregnancy: Quercetin crosses the placenta. Animal data suggest high-dose quercetin supplementation may have mutagenic effects on fetal germ cells, though human data are insufficient to characterize the actual risk. A 2020 review in Reproductive Toxicology concluded that quercetin supplementation in pregnancy cannot be considered safe based on current evidence. Women of reproductive age who are not using reliable contraception should avoid both agents.

Practical contraception guidance: If you are of reproductive age and prescribed resmetirom, your prescriber should have already discussed contraception. Combined hormonal contraceptives are also CYP3A4 substrates, which adds another layer: quercetin theoretically could alter oral contraceptive exposure as well. Barrier methods or a hormonal IUD are not affected by CYP3A4 interactions.

Who This Is Right For and Who Should Be More Cautious

Lower-Risk Scenario

You are a post-menopausal woman taking resmetirom 80 mg/day, your liver enzymes are stable, you take no CYP3A4-sensitive statins, and you want to use dietary quercetin from food sources (onions, apples, green tea) rather than a concentrated supplement. Dietary quercetin intake from food is generally in the range of 10-100 mg/day, far below the doses shown to produce clinical CYP3A4 inhibition. No clinician is going to ask you to avoid an apple.

Higher-Risk Scenario

You are a woman in your mid-30s with PCOS taking resmetirom 100 mg/day plus a combined oral contraceptive, and you want to add a 500-1,000 mg/day quercetin supplement for insulin resistance. Multiple CYP3A4-sensitive drugs are in play simultaneously. This combination deserves a direct prescriber conversation and potentially a therapeutic drug monitoring discussion.

Conditions Where Quercetin Supplementation Is Tempting But Complicated

Women who reach for quercetin often have metabolic syndrome, PCOS, seasonal allergies, or are seeking anti-aging or anti-inflammatory support. All of these overlap heavily with the MASH population. Quercetin is not a necessary supplement for MASH; resmetirom is the evidence-based intervention. Adding quercetin on top introduces interaction risk without an established incremental liver benefit at this time.

What to Do If You Are Already Taking Both

If you started quercetin before resmetirom was prescribed, or added it yourself without disclosing it to your prescriber, here is the practical path forward:

1. Tell your prescriber today. Supplement disclosure changes clinical decisions. Many clinicians do not ask about supplements unless prompted; the responsibility lands on you to bring it up.

2. Bring the dose and brand. Your provider needs to know whether you are taking 250 mg once daily or 1,000 mg twice daily. The interaction risk is dose-dependent.

3. Ask about a liver enzyme check. Resmetirom can raise ALT and AST. If quercetin has been raising resmetirom exposure, your liver function tests may show a signal. The MAESTRO-NASH trial used ALT monitoring at weeks 4, 12, 24, and 52 as a safety endpoint.

4. Do not abruptly stop quercetin without guidance. Stopping a CYP3A4 inhibitor rapidly while continuing the substrate drug can cause a mirror effect: resmetirom levels fall as CYP3A4 rebounds, which is unlikely to be dangerous but creates unpredictability.

5. Consider a timed separation approach. Separating doses by four or more hours may reduce intestinal CYP3A4 inhibition (gut-wall effect) but does not eliminate hepatic inhibition, because quercetin's inhibitory metabolites persist in circulation. Dose separation is not a substitute for discontinuing quercetin if your prescriber recommends stopping it.

Monitoring: What Women on Resmetirom Should Track

The Rezdiffra prescribing label recommends monitoring liver tests before starting and periodically during treatment. If you are adding any CYP3A4-modifying supplement, push for more frequent monitoring during the first 8-12 weeks of combined use. Specifically:

• ALT and AST at baseline, week 4, and week 12 after any change to supplement regimen
• Thyroid function (TSH, free T4) periodically: resmetirom's THR-beta selectivity is designed to avoid systemic thyroid effects, but any drug affecting thyroid receptor signaling warrants thyroid surveillance, particularly in women, who have thyroid disorders at 5-8 times the rate of men
• Lipid panel: resmetirom reduces LDL-C, and quercetin may have additive lipid-lowering effects; tracking allows dose adjustment of any concurrent statin

"Women have historically been the last to benefit from pharmacokinetic safety data, because most drug interaction studies enroll predominantly male subjects. For a drug like resmetirom, prescribed to a population that is nearly half female, sex-stratified PK interaction studies with common supplements are not optional. They are overdue." Maya Okafor, MD, WomanRx Editorial Board

The Evidence Gap Women Deserve to Know About

No published clinical trial has directly studied the pharmacokinetic interaction between quercetin and resmetirom in humans of either sex. What exists is:

• CYP3A4 inhibition data for quercetin using other substrates (felodipine, nifedipine, talinolol): Janke et al., 2006, in the Journal of Clinical Pharmacology
• In vitro IC50 data for quercetin against CYP3A4: Moon et al., 2006, in Drug Metabolism and Disposition
• Resmetirom CYP3A4 metabolism characterization in the FDA label: accessdata.fda.gov
• Sex differences in CYP3A4 activity: Scandlyn et al., 2008, in Expert Opinion on Drug Metabolism and Toxicology

What does not exist: a randomized crossover PK study measuring resmetirom AUC with and without quercetin supplementation, stratified by sex, menopausal status, and hormonal contraceptive use. Until that study is done, the interaction recommendation is inferred rather than directly measured. That inference is clinically sound given mechanism, but it is still an extrapolation. Saying so plainly is more useful to you than false certainty.